ERBB2 and breast carcinoma: Analysing the results for breast cancer subtypes, the majority were represented by patients with triple-negative tumours or with HER-2 overexpression (56.4%), the remaining were Luminal B/HER-2 negative (43.6%) and there were no patients with Luminal A cancer.